Jul 31, 2024 8:00am EDT Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
Jul 30, 2024 8:00am EDT Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
Jul 25, 2024 8:00am EDT Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
Jul 9, 2024 9:15am EDT Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
Jul 8, 2024 8:00am EDT Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
Jul 1, 2024 8:00am EDT Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
Jun 27, 2024 8:36am EDT Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
